{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:52:34Z","timestamp":1789455154291,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T00:00:00Z","timestamp":1348012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of the present study was to evaluate the virological efficacy of a 3\u2010month short\u2010course intensification with enfuvirtide (ENF) associated with an optimized background regimen (OBR) in treatment\u2010experienced patients infected with HIV\u20101 with multiple therapeutic failures. This was a prospective, randomized, open\u2010label multicenter trial including patients infected with HIV\u20101 and harboring a multi\u2010resistant virus that was still susceptible to at least 2 active compounds. Patients were randomized (1:1) to receive OBR\u2009+\u2009ENF or OBR alone. ENF was discontinued at Week 12. The primary endpoint was the proportion of patients with plasma viral load &lt;50\u2009copies\/ml at Week 24. Fifteen patients were randomized into the OBR group and 14 into the OBR\u2009+\u2009ENF group with a median viral load of 4.1\u2009log<jats:sub>10<\/jats:sub>\u2009copies\/ml and a median CD4+ cell count of 346\u2009cells\/mm<jats:sup>3<\/jats:sup>. The primary endpoint was achieved in 93% (14\/15) and 79% (11\/14) of patients, respectively. Eighty\u2010seven percent (13\/15) of patients had a viral load &lt;50\u2009copies\/ml as soon as Week 12 in the OBR group and 79% (11\/14) in the OBR\u2009+\u2009ENF group. At Week 12, the median CD4+ cell count was 327 in the OBR and 437 in the OBR\u2009+\u2009ENF groups and at Week 24 they were comparable. Intensification with ENF had no significant impact on PBMCs HIV\u2010DNA levels. A 3\u2010month short\u2010course intensified treatment with ENF did not improve Week\u201024 virological response in treatment\u2010experienced patients infected with HIV\u20101 harboring resistant viruses that were still susceptible to two antiretroviral drugs. J. Med. Virol. 84:1710\u20131718, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jmv.23388","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T11:21:45Z","timestamp":1348053705000},"page":"1710-1718","source":"Crossref","is-referenced-by-count":6,"title":["Lack of benefit of 3\u2010month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study"],"prefix":"10.1002","volume":"84","author":[{"given":"Laurence","family":"Morand\u2010Joubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boniface","family":"Giffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assia","family":"Samri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrina","family":"Pinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Triglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Innove Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00003"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21390"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2111"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60497-8"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn377"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363240-00005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000152835.17747.47"},{"key":"e_1_2_6_9_1","unstructured":"Department of Health and Human Services.2011.Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents. Available at:http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903107106"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200401230-00014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283445834"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/649569"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp182"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280b07b47"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69154-X"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/507312"},{"key":"e_1_2_6_19_1","unstructured":"JolyV FagardC DescampsD Colin de VerdiereN RaffiF TabuteauS.2010.Intensification of HAART through the addition of enfuvirtide in naive HIV\u2010infected patients with severe immunosuppression does not improve immunologic response: Results of a prospective randomized multicenter trial (APOLLO\u2010ANRS 130). 17th Conference on Retroviruses and Opportunistic Infections; February 2010 San Francisco California."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328013d9d7"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61048-4"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61047-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32832498d8"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/088922204322749567"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000185314.56556.c3"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328336ac2a"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.0174"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-11-S1-P29"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200304110-00005"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f0e3d0"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"e_1_2_6_34_1","unstructured":"SuC DeMasiR Heilek\u2010SnyderG MirallesD MelbyT DeeksSG CammackN.2004.Early additional CD4+ T cell count gains independently of viral suppression in the setting of enfuvirtide (T20) treatment. HIV DART 2004. Frontiers in Drug Development for Antiretroviral Therapies; Montego Bay Jamaica December 12\u201316 2004."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.10.4909-4920.2006"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"e_1_2_6_37_1","volume-title":"Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH. Recommandations du groupe d'experts","author":"Yeni P","year":"2010"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/656722"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.23388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:53:11Z","timestamp":1700527991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,19]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/jmv.23388"],"URL":"https:\/\/doi.org\/10.1002\/jmv.23388","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,19]]}}}